Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00846365 · ClinicalTrials.gov registry record · Phase 3

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3 study of Essential Hypertension, sponsored by Takeda.

Completed
Registry status
Phase 3
Development phase
1,085
Enrollment target
20
Study locations

NCT00846365 is a Phase 3 study of Essential Hypertension that has completed, run by Takeda. The registered enrollment target is 1,085 participants, above the 668-participant average among 8 other Essential Hypertension trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00846365, a Phase 3 study of Essential Hypertension, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 3
Development phase
1,085 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.

Conditions Studied

Essential Hypertension

Interventions

  • DRUG Azilsartan medoxomil and chlorthalidone
  • DRUG Olmesartan medoxomil-hydrochlorothiazide

Study Locations (20)

Florida

  • - Clearwater
  • - Jacksonville
  • - Jupiter
  • - Miami
  • - Ocala
  • - Pembroke Pines
  • - Plant City

Alabama

  • - Birmingham
  • - Haleyville
  • - Hueytown
  • - Jasper
  • - Tallassee

California

  • - Long Beach
  • - National City
  • - Roseville
  • - San Francisco
  • - San Jose

Arizona

  • - Green Valley
  • - Phoenix

Delaware

  • - Newark

Trial Details

FieldValue
Enrollment Target 1,085 participants
Start Date 2009-03
Est. Completion 2010-06
Phase Phase 3

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00846365

The ClinicalTrials.gov registry entry for NCT00846365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,085 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 668-participant average among 8 other Essential Hypertension trials with a reported enrollment target (62% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Essential Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Azilsartan medoxomil and chlorthalidone is the first listed.

NCT00846365 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00846365 about?

NCT00846365 is a clinical study titled "Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension". The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.

What is the current status of trial NCT00846365?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,085 participants. The study started on 2009-03. Estimated completion is 2010-06.

What conditions does trial NCT00846365 study?

This clinical trial studies the following conditions: Essential Hypertension.

What interventions are being tested in trial NCT00846365?

The interventions under investigation include: Azilsartan medoxomil and chlorthalidone (DRUG), Olmesartan medoxomil-hydrochlorothiazide (DRUG).

Who is sponsoring clinical trial NCT00846365?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00846365 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Essential Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Essential Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.